Leap Therapeutics (Leap Therapeutics) Total Assets : $57.96 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Leap Therapeutics Total Assets?

Leap Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $57.96 Mil.

During the past 12 months, Leap Therapeutics's average Total Assets Growth Rate was -32.50% per year. During the past 3 years, the average Total Assets Growth Rate was -1.70% per year. During the past 5 years, the average Total Assets Growth Rate was -0.10% per year. During the past 10 years, the average Total Assets Growth Rate was 5.40% per year.

During the past 12 years, Leap Therapeutics's highest 3-Year average Total Assets Growth Rate was 48.30%. The lowest was -29.00%. And the median was 2.40%.

Total Assets is connected with ROA %. Leap Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -84.53%. Total Assets is also linked to Revenue through Asset Turnover. Leap Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Leap Therapeutics Total Assets Historical Data

The historical data trend for Leap Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Total Assets Chart

Leap Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

7.45

54.37

117.91

70.35

72.83

Leap Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															106.55	95.86	83.05	72.83	57.96

Leap Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Leap Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	60.141	+	12.684
	=	72.83

Leap Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	47.372	+	10.591
	=	57.96

Leap Therapeutics (NAS:LPTX) Total Assets Explanation

Total Assets is connected with ROA %.

Leap Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-55.28	/	( (72.825	+	57.963)	/ 2 )
	=	-55.28	/	65.394
	=	-84.53 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Leap Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (72.825	+	57.963)	/ 2 )
=	0	/	65.394
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Leap Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics (Leap Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (NAS:LPTX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

5MC:Germany 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.

Executives

Jason Baum	officer: Chief Scientific Officer	LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Patricia A. Martin	director	316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260
Christian M Richard	director	100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110
Richard Schilsky	director	LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Beigene, Ltd.	10 percent owner	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christine Granfield	officer: VP, Head of Reg Affairs/Qual	C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Mark O'mahony	officer: Chief Manufacturing Officer	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Cynthia Sirard	officer: Chief Medical Officer	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher Mirabelli	director, 10 percent owner, officer: CEO,Pres,Chairman of the Board	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Augustine Lawlor	10 percent owner, officer: Chief Operating Officer	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Douglas E Onsi	10 percent owner, officer: CFO,Gen Counsel,Treas, Sec.	C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Healthcare Ventures Ix, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142